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Abstract 
Protein signalling between tissues, or tissue cross-talk is becoming 
recognised as a fundamental biological process that is incompletely 
understood. Shotgun proteomic analyses of tissues and plasma to explore 
this concept are regularly challenged by high dynamic range of protein 
abundance, which limits the identification of lower abundance proteins. In this 
viewpoint article, we highlight how a focus on proteins contained within 
extracellular vesicles (EVs) not only partially addresses this issue, it can 
reveal a underappreciated complexity of the circulating proteome in various 
physiological and pathological contexts. Furthermore, we highlight how 
quantitative proteomics can inform EV mediated cross talk and stress the 
importance of high coverage, sensitive proteomic analyses of EVs to identify 
both the optimal methods to isolate EV subtypes of interest and proteins that 
characterise them. 
 
  
Proteins in inter-tissue cross-talk 
 
Fundamental to the maintenance of homeostasis is the complex and 
coordinated signalling between endocrine glands and other tissues. Proteins 
or peptides such as insulin, glucagon and oxytocin, and their receptors, are 
therefore the foundation of endocrinology and inter-tissue cross talk. While the 
majority of focus in the field has been on protein (and steroid) secretions of 
widely recognised endocrine glands, such as the pancreas and pituitary, 
landmark findings have also implicated other tissues in endocrine –like roles. 
Indeed, the identification of adipokines, such as Leptin[1] and Adiponectin[2], 
myokines such as IL6[3] and Myonectin[4] and hepatokines such as Follistatin[5] 
and FGF21[6], widen interest in tissue protein secretion and fully implicate 
inter tissue protein signalling as a fundamental biological process that 
warrants further investigation. 
 
Proteomic approaches to investigating tissue cross talk 
 
The intricate, but vast coordinated signalling between tissues is clearly highly 
complex. However, a deeper understanding of these processes, particularly in 
the contexts of so-called ‘lifestyle diseases’ such as obesity and metabolic 
syndrome[7], has great potential in the discovery of novel therapies. Illustrating 
the challenge facing research in this area, a deep, integrated ‘omics’ analysis 
of the human tissue proteome reveals that a larger proportion of tissue-
enriched proteins are secreted or membrane spanning than are intracellular[8]. 
The magnitude of the human secretome is clearly vast, suggesting a broad 
range of tissue cross talk remains largely unexplored. Unbiased, hypothesis 
free and high coverage proteomic experiments lend themselves in this regard 
and in an attempt to characterise the secretome of various tissues. 
Accordingly, several groups have applied mass spectrometry analyses to 
reductionist, in vitro models of tissues such as skeletal muscle[9], Liver[10] and 
adipose[11]. However, in vitro models, particularly considering secretion as a 
coordinated process, can lack physiological relevance. Direct analyses of 
blood samples, especially when sampled across tissues via careful 
cannulation[12] likely offers the most insightful view of tissue protein secretion. 
That said, this approach also comes with considerable technical challenges.  
Proteins exist in plasma across a massive dynamic range of a minimum of 10 
orders of magnitude[13] with albumin constituting roughly half the total protein 
mass[14]. Small proteins involved in tissue cross talk, such as cytokines, 
generally circulate in the pg/ml range. Despite rapid advances in mass 
spectrometry technology in recent years, accurate quantitation of such 
proteins at the very bottom of this dynamic range, in an unbiased, untargeted 
manner, has largely been impossible to date.  
 
Proteomic analysis of extracellular vesicles – a convenient side step of the 
dynamic range issue. 
 
By and large, the simplest and quickest iteration of mass spectrometry based 
proteomics on plasma, so called single shot LC MS-MS, generally leads to the 
identification of no more than a few hundred proteins. While this type of 
analysis can be improved via depletion of abundant plasma proteins via 
immunoaffinity columns or beads, poor antibody specificity or affinity of 
proteins to albumin itself can result in a poorly representative sample[14]. 
Extensive fractionation, at the protein or peptide level is another option, but 
this can also magnify analysis time and limit throughput[15]. An alternative is to 
focus more closely on the constituents of blood and carry out fractionation 
prior to commencing the lysis, reduction, alkylation and digestion of proteins 
typical in proteomic sample processing. Generally, cells are removed from 
blood via centrifugation and the resultant plasma is assumed to contain 
protein, lipid and metabolites representative of the site of blood collection at 
that time. However, extracellular vesicles (EVs) of varying size and cellular 
origin are also present, and are increasingly recognised as important carriers 
of nucleic acid, lipid, metabolites and pertinently, proteins. Importantly, EVs 
can be isolated from plasma with relative ease, largely depleting the plasma 
sample of high abundance proteins. A focus on the proteins circulating in EVs, 
at least from an analytical perspective, represents a convenient sidestep of 
the problems associated with obstructive, high dynamic range and facilitates a 
deeper look into the circulating ‘secretome’. Vesiclepedia, an online 
compendium[16] of EV protein identifications across 54 studies, lists 306 
proteins identified via a range of analytical and isolation methods. When 
compared with the 8548 proteins identified in EVs across all cell types and 
tissues (Figure1), this, in many ways demonstrates the technical difficulty 
encountered in analysing EVs derived from plasma. That said, several 
groups, including our own, have recently made use of the rapid 
advancements in mass spectrometry technology to gain deeper insight into 
the circulating EV proteome in various physiological and pathological 
contexts[17, 18, 19]. 
  
Rethink on the circulating secretome? 
While there are, undoubtedly some gaps in our knowledge of classical protein 
secretion, it is largely a well-characterised process involving the recognition of 
N terminal amino acid signal sequences by the signal recognition particle 
(SRP), subsequent processing in the endoplasmic reticulum and golgi 
apparatus and eventual release into the extracellular environment[20]. Such is 
the apparent uniformity of signal or leader sequences in secreted proteins, it 
is possible to predict, via algorithms, their presence in proteins with known 
amino acid sequences[21]. In the context of identifying the secretome of a 
particular tissue therefore, one avenue of discovery is to identify tissue 
expression of mRNA or proteins in response to various physiological or 
pathological stimuli and screen, via bioinformatic means, for the presence of a 
signal peptide to inform which proteins are likely secreted. This approach has 
been adopted with success in skeletal muscle in the search for myokines or 
proteins secreted in response to contraction and exercise[22]. While this 
approach clearly has some merit, our recent, in depth analysis of the 
circulating EV proteome in humans[19] emphasises why a sole focus on 
proteins involved in classical secretion may underestimate the extent of the 
circulating proteome. In isolated small vesicles and exosomes of a size range 
of 50-350nm, we identified over 5000 proteins at a false discovery rate of 
1%[19]. Analysis of the amino acid sequence of each of these proteins via the 
SignalP server[21] predicted the presence of a signal peptide in just 16% of all 
protein identifications[19]. While the method of EV isolation, centrifugation, 
possibly led to some contamination with non EV proteins in these samples, 
the identification of such a high number of apparently non-secreted proteins in 
circulation suggests EVs provide a way in which cells can interchange 
proteins independently of classical secretion. So not only are secreted 
proteins of interest in understanding tissue cross talk, a new avenue, that 
being EV mediated protein exchange, may also be highly relevant. Indeed, 
the identification of thousands of proteins in EVs, in the human circulation, via 
in depth, high coverage UHPLC-MS/MS [17, 19], supports the existence of 
complex tissue cross talk as a fundamental biological process. 
 
Using quantitative proteomics to determine specific EV protein tissue uptake 
Of course, identifying vast numbers of proteins within EVs in plasma does not 
provide specific evidence of tissue cross talk per se. The field is therefore 
challenged to identify techniques by which tissue specific release and uptake 
of proteins in EVs can be characterised. With regard to the latter, quantitative 
proteomic approaches can make a contribution. For example, stable isotope 
labelling with amino acids in cell culture, or SILAC[23], has, in some ways been 
superseded by multiplexed isobaric[24] or non-labelled[25] quantitative 
approaches to mass spectrometry based proteomics. However, metabolic 
labelling with stable isotope amino acids provides a unique scenario whereby 
labelled cells in vitro or labelled rodents in vivo[19, 26] release EVs containing 
proteins that are distinguishable in mass spectrometry analyses, owing to 
their heavier mass (Figure 2B). Quantitative proteomic analyses of cells or 
tissues exposed to labelled EVs can therefore indicate not only the extent of 
EV derived protein uptake, but also the adhesion molecules potentially 
mediating this transfer[19]. This represents another example by which, 
unbiased, shotgun proteomics can inform EV mediated tissue cross talk. 
 
Searching for optimal EV isolation methods benefits optimal proteomic 
analyses 
 
The EV field is a rapidly growing one, as researchers recognise the 
importance of cell to cell communication via vesicles in both physiological and 
pathological contexts[27]. However, one frequent observation is the lack of 
consistency in isolation methodologies or validated controls identifying EV 
subsets[28]. This has led to confusion in nomenclature as to what represents, 
for example, an exosome or microparticle, which may have differing functional 
properties[29]. One approach to subjugate this issue is to isolate EV subtypes 
via a range of centrifugation, density gradient, or immunoaffinity methods and 
carry out unbiased proteomic analyses on each, with a view to identifying 
consistent EV markers for each subtype. While there have been some 
excellent contributions in this area, using EV samples from a range of cell 
lines[30, 31], proteomic coverage in these studies varies widely. Since the 
absence of a specific protein in EV subsets is as informative as its presence, 
researchers should take care in interpreting proteomic data when sample 
preparation, instrument performance, or both might be limiting the observable 
proteome. For example, current consensus in the field suggests that for 
isolation of ~100nm exosomes, centrifugation should be at greater than 
100,000g for over an hour. However, we have recently shown, in high 
coverage UHPLC-MS/MS analyses of EVs isolated from human plasma, that 
exosome and small vesicle markers such as TSG101, SDCBP, CD9 and 
PDCD6IP (ALIX) are reproducibly detected in samples isolated at just 
20,000g in a standard laboratory micro-centrifuge (Figure 2A, Table 1)[19]. 
These data suggest that, while EV isolation methods such as 
ultracentrifugation through a density gradient[32], size exclusion 
chromatography[33], or immmuno-isolation[30] will undoubtedly provide a more 
pure enrichment of small vesicles, adopting high quality proteomic 
methodologies allows the researcher to carry out exosome and small vesicle 
research in simple and conveniently derived EV samples.  Furthermore, 
experiments attempting to identify reproducible protein markers of different 
cell EV subtypes or proteins that might be mediating their biological action in 
various physiological and pathological scenarios can greatly benefit highly 
optimised, high coverage proteomic analyses. Encouragingly, recent, new 
acquisition methods demonstrate large improvements in the coverage and 
speed of single shot quantitative proteomics[34], suggesting that such analyses 
of EV subtypes can make telling contributions to the growing research field of 
EV mediated tissue cross talk. 
 
In conclusion, proteomic analyses of plasma continue to broaden the size of 
the known circulating proteome in various physiological and pathological 
states. Recent observations of a large number of proteins in circulation in EVs 
reminds the field that protein exchange between tissues, or tissue cross talk, 
might well be occurring independently of classical protein secretion. 
Furthermore, as the depth of coverage and accuracy of quantitative proteomic 
analyses continues to improve, it is likely that these approaches can greatly 
inform critical aspects of EV biology and help delineate specific tissue cross 
talk mediated by EVs. 
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Figure Legends 
 
Figure 1: Representation of proteins identified in EVs isolated from plasma in 
the context of the entire Vesiclepedia database[16]. Data were extracted from 
the Vesiclepedia database and visualised in the Funrich program[35] 
 
Figure 2: Proteomic approaches to the determination of tissue cross talk via 
extracellular vesicles (EVs). (A) Plasma is derived from participants using 
conventional means and EVs isolated via high-speed centrifugation 
interspersed by washing in phosphate buffered saline. The EV pellets are 
then lysed, reduced, alkylated and the protein contents digested via proteases 
‘in solution’. Optimised, single shot analyses on an Orbitrap mass 
spectrometer can facilitate great insight into protein release into circulation via 
EVs. (B) To examine specific interchange of proteins between cells and 
tissues, SILAC labelled cells and mice generate EVs containing ‘heavy’ 
proteins distinguishable in LC-MS/MS analyses. Pulse chasing of these EVs 
into different, unlabelled cells or mouse recipients, via LC-MS/MS screening 
of recipient cells and tissues provides insight into specific protein delivery via 
EVs. 
 
Table 1 Proteins commonly known as exosome markers reproducibly 
identified in EVs isolated at 20,000g from plasma of three healthy human 
donors. Listed are the Uniprot identifier for each exosome marker, the IBAQ 
intensity recorded in the EV sample from each subject, the number of unique 
peptide sequences associated with that marker and the number of 
sequencing events, or MS/MS, used to derive this information. For full 
methodological approach, see[19]. Associated mass spectrometry data are 
available via the PRIDE partner repository with the dataset 
identifier PXD006501. 
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Table 1 
   Subject 1 Subject 2 Subject 3 
Gene TSG101 IBAQ intensity (log2) 23.1 22.9 25.5 
Uniprot ID Q99816 Unique peptides 2 2 6 
  MS/MS count 3 2 8 
Gene SDCBP IBAQ intensity (log2) 25.0 26.6 24.5 
Uniprot ID O00560 Unique peptides 2 1 0  
  MS/MS count 6 13 3 
Gene CD9 IBAQ intensity (log2) 33.2 32.9 33.9 
Uniprot ID P21926 Unique peptides 6 7 5 
  MS/MS count 15 22 19 
Gene PDCD6IP 
(ALIX) 
IBAQ intensity (log2) 26.7 25.5 27.6 
Uniprot ID Q8WUM4 Unique peptides 24 12 25 
  MS/MS count 27 19 31 
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